Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen. The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”. After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4. Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

FilterHomeInhibitory Antibodies
Anti-Mouse PD-1 Antibody (RMP1-14)
T78269
Anti-Mouse PD-1 Antibody (RMP1-14) is an IgG2a antibody inhibitor against mouse PD-1 and can block PD-1 PD-L1 signaling.
  • $64
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Trastuzumab
T9912180288-69-1
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • $157
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Cetuximab
T9905205923-56-4
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
  • $197
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Pembrolizumab
T99081374853-91-4
Pembrolizumab (MK-3475) is a highly selective humanized monoclonal antibody that antagonizes PD-1. It can block the PD-1 protein on T cells and prevent their interaction with PD-L1 on cancer cells.
  • $218
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Atezolizumab
T99021380723-44-3
Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.
  • $228
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Bevacizumab
T9904216974-75-3
Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.
  • $129
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Datopotamab deruxtecan
T397302238831-60-0
Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.
  • $1,060
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Dupilumab
T136661190264-60-8
Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.
  • $239
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Evolocumab
T99201256937-27-5
Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.
  • $397
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Tezepelumab
T773591572943-04-4
Tezepelumab (AMG 157) is a humanized monoclonal antibody (IgG2λ) targeting TSLP that prevents TSLP from interacting with its heterodimer receptor. Tezepelumab can be used to study advanced asthma disease.
  • $1,060
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Nivolumab
T9907946414-94-4
Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.
  • $182
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Olamkicept
T732091702282-14-1
Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that selectively inhibits interleukin 6 (IL-6) trans-signaling by binding to the soluble IL-6 receptor IL-6 complex.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Human IgG1 kappa, Isotype Control
T78242
Human IgG1 kappa, Isotype Control is a humanized IgG-like monoclonal antibody and an isotype control antibody for human IgG1κ.
  • $247
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Avelumab
T99031537032-82-8
Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.
  • $289
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Adalimumab
T9901331731-18-1
Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
  • $213
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Infliximab
T9921170277-31-3
Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.
  • $98
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Brentuximab
T767182088770-90-3
Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.
  • $297
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Rituximab
T9910174722-31-7
Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.
  • $229
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Abelacimab
T768942098724-83-3
Abelacimab (MAA868), a fully human IgG1 monoclonal antibody that binds to and blocks the activation of FXI, is an anticoagulant used in the study of thromboembolic diseases.
  • $228
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Opicinumab
T774161422268-07-2
Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.
  • $198
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Sacituzumab
T353971796566-95-4
Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.
  • $163
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Alirocumab
T99161245916-14-6
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
  • $372
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Disitamab vedotin
T395952136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.
  • $347
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Zolbetuximab
T9901A-0051496553-00-4
Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.Zolbetuximab is used in the study of gastrointestinal adenocarcinomas and pancreatic tumors.
  • $263
In Stock
Size
QTY